Melane Sampson, Author at BioTuesdays

Developments

Cancer Cell highlights preclinical data of Tonix’s mTNX-1700 in gastric cancer models

Tonix Pharmaceuticals (NASDAQ: TNXP) has announced the publication of a paper in the peer-reviewed journal Cancer Cell, presenting data demonstrating that treatment with murine TNX-1700 (mTNX-1700) increased survival...

July 2, 2025

Developments

Clearmind doses first patient in trial of MEAI-based treatment for AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that the first patient has been dosed in its Phase 1/2a clinical trial of its proprietary MEAI-based oral drug candidate, CMND-100, for the treatment of alcohol...

July 2, 2025

Developments

Medical City Dallas Hospital enhances surgical precision with Perimeter’s OCT imaging technology

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that Medical City Dallas Hospital—an award-winning, 899-bed acute care hospital in the Dallas-Fort Worth area—has adopted the company’s current...

July 2, 2025

Feature

Dotmatics empowering life-changing discoveries with next-gen therapeutic research solution

Closely held Dotmatics is transforming the therapeutic research and development landscape with Luma, a groundbreaking solution in multimodal data management with the potential to address long-standing scientific...

July 1, 2025

Developments

Artelo reports positive first-in-human results for novel non-opioid pain therapy

Artelo Biosciences (NASDAQ: ARTL) has announced positive results from its first-in-human study evaluating its novel non-opioid candidate, ART26.12, for the treatment of persistent pain. ART26.12 is the first orally...

June 30, 2025

Developments

KalVista grants Pendopharm rights to commercialize sebetralstat for HAE

KalVista Pharmaceuticals (NASDAQ: KALV) has announced that it has entered into a licensing agreement with closely held Pendopharm to manage the regulatory approval process and commercialization of sebetralstat, an...

June 26, 2025

Developments

NMPA approves Theravance’s YUPELRI for COPD in China

Theravance Biopharma (NASDAQ: TBPH) has announced that China’s National Medical Products Administration (NMPA) has granted regulatory approval for YUPELRI, the company’s revefenacin inhalation solution for the treatment...

June 26, 2025

Developments

Clearmind adds leading Israeli clinical site to ongoing trial of CMND-100 in AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that it has added Tel Aviv Sourasky Medical Center (TASMC) to the list of clinical sites for its ongoing Phase 1/2a trial evaluating CMND-100—a proprietary MEAI...

June 24, 2025

Developments

Immunic reports positive long-term OLE data from trial of IMU-838 in RRMS

Immunic (NASDAQ: IMUX) has announced new, positive long-term open-label extension (OLE) data from its Phase 2 EMPhASIS trial of lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus...

June 24, 2025

Feature

VeriSIM delivering predictive insights to advance and de-risk drug development

Closely held VeriSIM Life is leveraging multi-disciplinary quantitative methods to predict patient outcomes and accelerate the discovery, development, and commercialization of transformative therapies. The company aims...

June 24, 2025

Author - Melane Sampson

Cancer Cell highlights preclinical data of Tonix’s mTNX-1700 in gastric cancer models

Clearmind doses first patient in trial of MEAI-based treatment for AUD

Medical City Dallas Hospital enhances surgical precision with Perimeter’s OCT imaging technology

Dotmatics empowering life-changing discoveries with next-gen therapeutic research solution

Artelo reports positive first-in-human results for novel non-opioid pain therapy

KalVista grants Pendopharm rights to commercialize sebetralstat for HAE

NMPA approves Theravance’s YUPELRI for COPD in China

Clearmind adds leading Israeli clinical site to ongoing trial of CMND-100 in AUD

Immunic reports positive long-term OLE data from trial of IMU-838 in RRMS

VeriSIM delivering predictive insights to advance and de-risk drug development

Subscribe